Table 2.

Summary of Mean Maximal Dermal Assessment Scores of the Safety Population

	Methylphenidate Transdermal System (MTS)
	10 mg/12.5 cm2 (n = 305)		15 mg/18.75 cm2 (n = 260)		20 mg/25 cm2 (n = 174)		30 mg/37.5 cm2 (n = 93)		Overall (N = 305)
Dermal Assessment	Currenta	Priorb	Current	Prior	Current	Prior	Current	Prior	Current	Prior
Dermal Response Scale, mean (± SD)c	0.9 (0.8)	0.3 (0.5)	1.0 (0.8)	0.4 (0.7)	1.2 (0.9)	0.4 (0.6)	1.2 (0.9)	0.5 (0.7)	1.4 (0.8)	0.8 (0.8)
n	296	296	260	260	170	170	92	92	303	303
Experience of Discomfort Scale, mean (± SD)d	0.2 (0.4)	0.1 (0.4)	0.3 (0.5)	0.2 (0.4)	0.3 (0.6)	0.2 (0.5)	0.5 (0.6)	0.3 (0.5)	0.6 (0.8)	0.4 (0.6)
n	295	295	260	260	170	170	92	92	303	303
Transdermal System Adherence Scale, mean (± SD)e	0.5 (0.9)		0.5 (0.9)		0.4 (0.7)		0.5 (0.7)		0.9 (1.1)
n	224		203		130		79		272

^aCurrent = MTS patch site at time of assessment. Note: MTS patch was clear, allowing for visual assessment.

^bPrior = previous day's treatment site.

^c0: no evidence of irritation; 1: minimal erythema; 2: definite erythema; 3: erythema and papules; 4: definite edema; 5: erythema, edema, and papules; 6: vesicular eruption; and 7: strong reaction beyond test site.

^d0: no discomfort; 1: mild discomfort; 2: moderate, but tolerable discomfort; and 3: severe, intolerable discomfort.

^e0: ≥ 90%, 1: ≥ 75% to < 90%, 2: ≥ 50% to < 75%, 3: < 50%, and 4: patch detached.